AAM to Congress: Reject 2019 Hatch-Waxman billThe Association for Accessible Medicines has told members of Congress that the Hatch-Waxman Integrity Act of 2019 would decrease patient access to generics and biosimilars. FDA launches track-and-trace pilotThe pilot will inform the development of the enhanced electronic, interoperable track-and-trace system for industry set to go into effect in 2023 as part of the Drug Supply Chain Security Act, the agency said. Teva unveils Alyq, its generic Adcirca Teva's generic of Eli Lilly's Adcirca is indicated to treat pulmonary arterial hypertension. J&J to include cost information in TV drug ads Janssen will include both the list price and potential patient out-of-pocket costs in future direct-to-consumer TV ads. CSS Health to offer medication adherence, compliance solutions CSS Health, Medicine-on-Time, and Clinical Support Services are joining together to offer medication therapy management solutions. Upsher-Smith, NASPA honor 40 pharmacists Forty pharmacists are being honored as 2018 NASPA Excellence in Innovation Award recipients. Cardinal Health posts 7% growth in Q2 Cardinal Health's second-quarter results saw growth being led by the company’s pharmaceutical segment. FDA approves Lupin’s generic Adcirca The Food and Drug Administration has cleared Lupin's generic Adcirca, which had a market value of about $474.3 million for the year ended December 2018. Ablynx gets FDA green light for Cablivi Ablynx's Cablivi is the first therapy for the treatment of adult patients with a rare blood clotting disorder. APhA revises guidelines on pharmacy-based immunizations The APhA has revised its immunization guidelines for pharmacies — marking the second time they have been updated since their adoption in 1997. First Previous 531 532 533 534 535 Next Last
